Evotec Announces New Nomination to Board of Directors

Nomination of Dr. Wolfgang Hofmann as unbiased Supervisory Board member to additional strengthen oversight and governance capabilities
Conclusion of cooperation settlement with MAK Capital following constructive discussions, reflecting Evotec’s dedication to open shareholder dialogue
Annual Normal Assembly to vote on the appointments of Supervisory Board members and proposed growth of Supervisory Board, supporting efficient oversight and lengthy‑time period worth creation

HAMBURG, GERMANY / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt:EVT) immediately introduced the nomination of Dr. Wolfgang Hofmann for election as an unbiased member of the Supervisory Board on the firm’s upcoming Annual Normal Assembly (AGM) to be held on June 11, 2026. The AGM agenda additionally contains the beforehand introduced nomination of Dieter Weinand as Chairman of the Supervisory Board, in addition to a proposal to extend the dimensions of the Supervisory Board from six to seven members.

Following constructive discussions, Evotec has entered right into a cooperation settlement with MAK Capital Fund LP (“MAK Capital”), a key shareholder of the corporate. Underneath the phrases of the settlement MAK Capital has agreed to customary voting and cooperation commitments amongst different provisions.

Prof. Dr. Iris Löw-Friedrich, Chairwoman of Evotec’s Supervisory Board, stated:

“We’re happy to appoint Wolfgang for election on the upcoming AGM. His appointment would contribute oversight and governance capabilities by way of further business, scientific and governance experience, complementing our current Board construction as we proceed to implement our transformation plans to develop shareholder worth. The settlement reached, displays Evotec’s dedication to constructive shareholder engagement, supporting the lengthy‑time period success of the Firm.”

Michael A. Kaufman, Chief Government Officer of MAK Capital, stated:

“We admire the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We stay up for persevering with our collaboration with the Supervisory Board and Administration Board to help Evotec’s ongoing transformation.”

About Evotec SE

Evotec is a life science firm that’s pioneering the way forward for drug discovery and improvement. By integrating breakthrough science with AI-driven innovation and superior applied sciences, we speed up the journey from idea to remedy – quicker, smarter, and with larger precision. Our experience spans small molecules, biologics, cell therapies and related modalities, supported by proprietary platforms akin to Molecular Affected person Databases, PanOmics and iPSC-based illness modeling. With versatile partnering fashions tailor-made to our prospects’ wants, we work with all High 20 Pharma firms, over 800 biotechs, tutorial establishments, and healthcare stakeholders. Our choices vary from standalone companies to completely built-in R&D applications and long-term strategic partnerships, combining scientific excellence with operational agility. By way of Simply – Evotec Biologics, we redefine biologics improvement and manufacturing to enhance accessibility and affordability. With a robust portfolio of over 100 proprietary R&D property, most of them being co-owned, we concentrate on key therapeutic areas together with oncology, cardiovascular and metabolic illnesses, neurology, and immunology. Evotec’s international crew of greater than 4,500 specialists operates from websites in Europe and the U.S., providing complementary applied sciences and companies as synergistic facilities of excellence. Be taught extra at http://www.evotec.com and comply with us on LinkedIn and X/Twitter @Evotec.

Ahead-looking statements

This announcement accommodates forward-looking statements regarding future occasions, together with the proposed providing and itemizing of Evotec’s securities. Phrases akin to “anticipate,” “imagine,” “may,” “estimate,” “count on,” “intend,” “might,” “would possibly,” “plan,” “potential,” “ought to,” “goal,” “would” and variations of such phrases and related expressions are supposed to determine forward-looking statements. Such statements embrace feedback concerning Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D bills. These forward-looking statements are based mostly on the data obtainable to, and the expectations and assumptions deemed cheap by Evotec on the time these statements have been made. No assurance could be provided that such expectations will show to have been right. These statements contain identified and unknown dangers and are based mostly upon various assumptions and estimates, that are inherently topic to vital uncertainties and contingencies, a lot of that are past the management of Evotec. Evotec expressly disclaims any obligations or endeavor to launch publicly any updates or revisions to any forward-looking statements contained herein to replicate any change in Evotec’s expectations with respect thereto or any change in occasions, circumstances or circumstances on which any assertion relies.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of World Communications & Investor Relations
[email protected]

SOURCE: Evotec SE